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The development of RBC autoantibodies resulting from or asso-
ciated with allogeneic blood transfusions is not an easily deter-
mined complication of RBC transfusions. This report discusses 
one patient who developed RBC autoantibodies in association 
with an allogeneic blood transfusion and alloimmunization lead-
ing to a temporary bystander immune hemolysis. A 72-year-old 
woman was hospitalized as a result of severe anemia and received 
two units of ABO- and D-compatible RBCs. She had a history of 
two pregnancies 40 years before, but no history of RBC transfu-
sion, and her antibody screen was negative. On the tenth day after 
transfusion her hemoglobin dropped, and alloanti-c was identi-
fied in her serum and eluate. At this time she received another 





, K:-1). After 48 hours, she developed joint pain, pyrexia, 
and hemoglobinuria, and her Hb dropped from 9.2 g/dL to 5.3 g/
dL. The direct antiglobulin test was positive, an IgG autoantibody 
was present in the eluate, and the antibody investigation revealed 
the presence of anti-Jkb in addition to the previously identified 
alloanti-c. Her genotype was determined, and, based on the find-
ings, two additional units were selected, found to be compatible, 
and transfused without incident. Transfusions were discontinued, 
and she was treated with IVIG and corticosteroids. Her Hb in-
creased to 9.7 g/dL, and the patient made an uneventful recovery. 
It was concluded that transfusion of incompatible RBCs induced 
the formation of an autoantibody in this patient, resulting in lysis 
of bystander RBCs. The need for additional blood transfusion was 
successfully avoided by treatment with IVIG, steroid therapy, and 
rituximab. Immunohematology 2009;25:9–12.
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The presence of alloantibodies in chronically transfused patients and pregnant women is a well-recognized complication of RBC transfusions and pregnancies 
and, as such, is unrelated to the concomitant autoantibod-
ies. In contrast to alloimmunization, the risk of autoimmu-
nization resulting from or associated with the development 
of alloantibodies is poorly understood; however, RBC auto-
immunization and the development of autoimmune hemo-
lytic anemia (AIHA) should be recognized as a complication 
of allogeneic RBC transfusion.1
Recent studies of patients with multiple transfusions, 
such as those with sickle cell anemia, have drawn atten-
tion to the association between autoimmunization and al-
loimmunization.2–5 RBC autoimmunization has also been 
described in both animal and human experimental models 
in which introduction of incompatible RBCs induced both 
alloantibody and autoantibody formation.6–10
The development of AIHA concurrent with or shortly af-
ter alloimmunization from blood transfusions has also been 
reported, and one possible mechanism to explain this phe-
nomenon is that alloantibody binding to transfused RBCs 
could lead to conformational changes in antigenic epitopes 
that then stimulate production of an autoantibody.1 The 
term bystander immune hemolysis is applied when AIHA 
occurs after exposure to alloantigens.11
This phenomenon, which has been recognized in the 
medical literature for many years, seems to receive little at-
tention although it is clinically very important and it touch-
es on some basic immunologic principles that might have 
broader implications than has been previously realized.12
We report one case of severe, life-threatening bystand-
er immune hemolysis associated with the development of 
an autoantibody in association with allogeneic blood trans-
fusions and alloimmunization.
Case Report
A 72-year-old white woman with a history of coronary 
artery disease, hypertension, diabetes mellitus, and angio- 
dysplasia was hospitalized as a result of severe anemia, 
weakness, chest discomfort, dyspnea, and acute lower gas-
trointestinal bleeding. On physical examination, the patient 
was pale, tachycardic, and normotensive with normal oxy-
gen saturation by pulse oximetry. Her admission laboratory 
evaluation revealed an Hb of 7.9 g/dL, Hct of 24%, reticu-
locyte count of 3.1%, WBC count of 4.53 × 103/μL, plate-
let count of 343 × 103/μL, blood urea nitrogen of 21 mg/
dL, and creatinine of 0.7 mg/dL. She received two units of 
ABO- and D-compatible blood. No RBC alloantibodies were 
detected, and her RBCs did not react in the DAT before this 
transfusion. No symptoms occurred during the transfusion. 
Ten days later, the patient was readmitted with slight signs 
and symptoms of hemolysis, and there was no evidence of 
blood loss. The clinical investigation revealed no history 
of previous RBC transfusion, but she had a history of two 
pregnancies 40 years ago. The patient’s Hb level was 8.2 g/
dL, LDH was 1509 IU/L, nonconjugated bilirubin was 1.5 
mg/dL, and hemoglobinemia was 8.9 mg/dL; alloanti-c was 
identified in her serum and eluate. Clinical and serologic 
results demonstrated a delayed hemolytic transfusion reac-
tion (DHTR) attributable to anti-c. At this time she received 
two additional units of compatible blood according to her 




, K:-1). After 48 hours, she 
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exhibited generalized musculoskeletal pain, pyrexia, and 
hemoglobinuria, and her Hb dropped from 9.2 g/dL to 5.3 
g/dL. The DAT was 4+; a warm IgG autoantibody that react-
ed with her RBCs and all panel cells by the IAT was present in 
the serum and eluate. A differential absorption method revealed 
the presence of the known alloanti-c coexisting with a newly 
identified alloanti-Jkb in her serum. Molecular analysis was 
performed, and she received two units of compatible blood 
according to her genotype (RHD, RHCE*C/C, RHCE*e/e, 
KEL*2/2, JK*A/A, FY*A/B, GYPB*S/s) without clinical 
or laboratory response. A clinical diagnosis of AIHA was 
made, and treatment was started on day 8 after the diag-
nosis with IVIG (0.4 g/kg for 5 days) and IV methylpredni-
solone (0.5 g for 5 days). Her Hb increased to 9.8 g/dL, but 
a chest discomfort persisted. She received two RBC units, 
and 48 hours after the transfusion her Hb dropped to 7.7 
g/dL. Transfusions were discontinued, and she was treated 
with rituximab (500 mg one time weekly for 1 month). After 
2 months, there was no evidence of hemolysis, her Hct re-
mained stable, and the laboratory tests revealed alloanti-c 




 Direct and indirect antiglobulin tests were performed 
by hemagglutination in tubes and in gel cards (DiaMed 
AG, Cressier sur Morat, Switzerland). Antisera and reagent 
RBCs were obtained from a variety of commercial companies 
(DiaMed AG; Gamma Biologicals Inc., Houston, TX; Frese-
nius Hemocare, São Paulo, Brazil). Eluate was performed 
using Gamma Elu Kit II (Gamma Biologicals Inc.) from pa-
tient RBCs. Differential absorptions were performed on the 
patient’s serum to remove the autoantibody, allowing the 
identification of the alloantibodies.
Molecular studies
 DNA was extracted from blood samples by using a kit 
(Easy DNA kit, Invitrogen, Carlsbad, CA) according to the 
manufacturer’s recommendations. Allele-specific PCR (AS-
PCR) and PCR-RFLP were used for RH, KEL, FY, JK, and Ss 
genotyping. The primers and the amplification conditions 
used for genotyping have been previously published.13
Results
Patient’s samples
 Before the first hemolytic transfusion reaction, the al-
loanti-c was not detected; most probably the antibody titer 
was very low and the antibody was undetectable by sero-
logic techniques. After the second hemolytic transfusion 





units, alloanti-c and alloanti-Jkb were found.
 The two alloantibodies were identified in the serum 
samples with PEG-IAT, GEL-LISS, and GEL-PAPAIN. 
After the first hemolytic episode, the patient’s RBCs were 
weakly reactive in the DAT (tube and gel) and alloanti-c 
was identified in the eluate, but after the second hemolytic 
episode, the DAT became strongly positive. The eluate from 
the posttransfusion sample demonstrated the presence of 
a warm IgG autoantibody that reacted with her RBCs and 
all panel cells, including all c– panel cells, by the IAT. Her 
serum was positive with all RBCs tested, and allogeneic 
adsorptions using selected RBCs with the same patient’s 
antigen profile according to the predicted phenotype from 
genotype results (RHD, RHCE*C/C, RHCE*e/e, KEL*2/2, 
JK*A/A, FY*A/B, GYPB*S/s) were performed to identify 
underlying alloantibodies. After allogeneic adsorptions on 
patient’s serum, alloanti-c and alloanti-Jkb were identified.
 After the third transfusion episode, even receiving two 
units of compatible blood according to her genotype, the 
DAT was still strongly positive (4+), and a panagglutinin 
was found in the eluate, suggesting the presence of the 
autoantibody.
RBC units
 A total of three transfusion episodes, during which six 
different RBC units were transfused, were analyzed retro-
spectively. In the first transfusion episode, crossmatches 
performed with serum from a pretransfusion sample and 
two units of ABO- and D-compatible RBCs were found to be 
repeatedly negative with PEG-IAT. In the second transfusion 
episode, crossmatches performed with the absorbed serum 
of the posttransfusion sample and two units of compatible 




, K:-1) were 
negative, and in the last transfusion episode, crossmatches 
performed with the absorbed serum of the posttransfusion 
sample and two units of compatible blood according to her 




, K:-1, Jk[b–]) were also negative. 
RBCs from the first donor unit were found to be c+ and 
Jk(b+), but the other five RBC units were c– and Jk(b–). 
Retrospectively, the transfusion that was most probably re-
sponsible for the immune response–induced alloantibody 
and autoantibody formation could be traced back to the 
first transfusion episode, when the c+ and Jk(b+) RBC units 
were administered.
Discussion
 This case demonstrates the development of AIHA after 
alloimmunization from blood transfusion and hemolytic re-
action. The autoimmune hemolysis was initially associated 
with the appearance of an alloantibody; anti-c was detected 
in an eluate prepared from the patient’s RBCs after the first 
DHTR. However, 10 days after the last compatible transfu-
sion, the DAT became strongly positive and an eluate pre-
pared from the patient’s RBCs indicated the presence of a 
warm IgG autoantibody, suggesting that it was responsible 
for the bystander hemolysis. The nadir levels of Hb and Hct 
during acute hemolysis were substantially lower than the 
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pretransfusion levels of Hb and Hct, indicating the destruc-
tion of autologous RBCs. Based on these observations, we 
believe that there is clinical evidence of autoimmune hemo-
lysis in the present case.
 The development of RBC autoantibodies and AIHA af-
ter transfusion was first described by Dameshek, in 1965,6 
when he observed a number of patients who exhibited a 
positive antiglobulin test after several transfusions. He sug-
gested that some of these reactions had the appearance of 
an autoimmune reaction, possibly because of cross-reacting 
antibodies. However, he stated that because the stimulation 
of exogenous antigen is required to set off the reaction and 
it is not self-perpetuating, such reactions are actually al-
loimmune reactions resulting in a temporary state of pseudo- 
auto immunity.
 There is a significant body of literature on the devel-
opment of RBC autoantibodies and AIHA after transfusion 
and it is of interest to keep in our minds the possibility of 
autoimmunity and bystander immune hemolysis. Different 
reports describe the temporary presence of autoantibod-
ies and AIHA, with either spontaneous resolution in weeks 
or months or complete response to initial therapy. Some 
reports describe acute fatal hemolysis, and only a few de-
scribe AIHA or autoantibodies persisting for an indefinite 
time.14,15
 Data from animal experiments16–18 show the induction 
of RBC autoantibodies in mice immunized with rat RBCs. 
The mice developed autoantibodies, as demonstrated by a 
positive IAT and DAT. Some mice exhibited AIHA. It is of 
great interest that persistence of the positive DAT required 
that the mice be repeatedly immunized with rat RBCs. After 
immunization was interrupted, the serologic tests returned 
to normal. When the mice were immunized again with rat 
RBCs, there was a burst of autoantibody production, and 
then after 4 to 5 weeks, autoantibody production ceased.
 There are several published reports on humans. La-
lezari et al.19 published a report of a 40-year-old woman 
who had a partial D phenotype and had been transfused 
with several units of D+ blood, and 10 years later, received 
three additional units. She had a high titer of anti-D, and this 
anamnestic response was associated with the development of 
an autoantibody. The DAT, which had been negative before 
transfusion, became positive and remained so for 6 months. 
Chaplin et al.20 described 5 patients with sickle cell disease 
who exhibited AIHA. All patients had made alloantibodies 
in response to transfusion before they made autoantibod-
ies. The patients with AIHA experienced severe anemia and 
had increased reticulocyte counts. All patients responded to 
steroid therapy. After discharge the DATs became negative. 
Argiolu et al.21 reported 4 patients with thalassemia major 
in whom they diagnosed AIHA on the basis of an increase 
in transfusion requirement, associated with the presence 
of RBC autoantibodies. All the patients were treated with 
IVIG therapy, and 3 responded as indicated by normaliza-
tion of the blood consumption. Wodzinski et al.22 described 
an extraordinary case of paroxysmal cold hemoglobinuria 
(PCH) after an ABO-incompatible transfusion. The authors 
suggested that the ABO HTR triggered or exacerbated an 
autoimmune response manifesting as PCH. Dameshek and 
Levine23 reported a case in which successive transfusions 
resulted in extreme, almost fatal, hemolysis. In contrast 
to their later conclusions, Dameshek and Levine23 at that 
time suggested that an irreversible autohemolytic process 
had been established by the multiple transfusions and that 
this report6 was published well before the description of au-
toabsorption or alloadsorption of sera containing autoanti-
bodies to detect the presence of alloantibodies, which could 
have been the cause of the hemolysis.
 Young et al.1 drew attention to the association between 
autoimmunization and alloimmunization that occurs com-
monly but only manifests obvious clinical ill effects on rare 
occasions. The phenomenon deserves much more atten-
tion because it involves basic immunologic mechanisms 
that have broad implication. Our case reinforces that RBC 
autoimmunization and the development of AIHA could be 
recognized as an adverse effect of allogeneic RBC transfu-
sion. A strategy that minimizes exposure to allogeneic blood 
transfusion would reduce risks of RBC autoimmunization 
and development of new alloantibodies.
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